Mr. Dean Sullivan:

At the meeting on 23 April, Mr. Pollock noted that the acquisition of GMP approval by the end of June was at significant risk. Mr. Connaghan, as chair, asked about the scale of the financial risk involved. Mr. Pollock advised that it was too early to estimate at that point but agreed to provide clarity about the timeline and financial risk by June, as per the minutes. That was in April 2018. That is why it is not particularly helpful to start in May, when I took over the role.